secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-022910
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum Therapeutics Q3 net loss $23.7M; cash $221.8M; selected 12mg dose for FTX-6058 SCD trial
--------------------------------------------------------------------------------

- Net loss $23.7M vs $20.7M year ago; collaboration revenue fell to $1.2M from $4.9M due to Acceleron wind-down.
- Cash, equivalents, and marketable securities $221.8M; cash runway guidance extended into late 2024.
- Completed equity raise of ~$80.8M net proceeds in August 2022.
- Selected 12mg as dose for next FTX-6058 Phase 1b cohort in sickle cell disease; enrollment continues.
- Appointed Santiago Arroyo as CMO and Jeff Jacobs as CSO; losmapimod Phase 3 REACH trial enrollment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/0000950170-22-022910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000095017022022910/fulc-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer